(Q42502892)

English

Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 November 2017

Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study (English)

1 reference

Europe PubMed Central

1 November 2017

0 references

nodular basal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

S van der Geer

1

1 reference

Europe PubMed Central

1 November 2017

J Martens

2

1 reference

Europe PubMed Central

1 November 2017

J van Roij

3

1 reference

Europe PubMed Central

1 November 2017

E Brand

4

1 reference

Europe PubMed Central

1 November 2017

J U Ostertag

5

1 reference

Europe PubMed Central

1 November 2017

M E J M Verhaegh

6

1 reference

Europe PubMed Central

1 November 2017

H A M Neumann

7

1 reference

Europe PubMed Central

1 November 2017

G A M Krekels

8

1 reference

Europe PubMed Central

1 November 2017

language of work or name

0 references

publication date

21 May 2012

1 reference

Europe PubMed Central

1 November 2017

British Journal of Dermatology

1 reference

Europe PubMed Central

1 November 2017

167

1 reference

Europe PubMed Central

1 November 2017

1

1 reference

Europe PubMed Central

1 November 2017

110-115

1 reference

Europe PubMed Central

1 November 2017

Basal and squamous cell carcinomas. What every primary care physician should know

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

What lies beneath? A lesson for the clinician. Intraoperative frozen section appearance of persistent basal cell carcinoma after apparent cure with imiquimod 5% cream

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Unit cost of Mohs and Dermasurgery Unit.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10924.X

21 January 2018

Identifiers

10.1111/J.1365-2133.2012.10924.X

1 reference

Europe PubMed Central

1 November 2017

1 reference

Europe PubMed Central

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42502892&oldid=1959960640"